Corticosteroids as first treatment in MCD, FSGS and IgAN: when and how. Long term side effects by Claudio Ponticelli
/in NEP Summary Articles /by ERASGLT2 inhibition in CKD: Our chance to make a difference – Organised by CHANGE IME in partnership with Leicester Diabetes Centre, funded by an unrestricted educational grant from AstraZeneca
/in NEP Summary Articles /by ERAClinical Conundrums in aTypical HUS – Organised by ALEXION PHARMA GMBH
/in NEP Summary Articles /by ERAK+: Recurrence, Restriction and Fluctuation. Organised by CHANGE IME in partnership with Leicester Diabetes Centre, funded by an unrestricted educational grant from AstraZeneca
/in NEP Summary Articles /by ERAExpert approaches to management across the CKD-MBD continuum – Organised by Vifor Fresenius Medical Care Renal Pharma Ltd.
/in NEP Summary Articles /by ERACOVID-19 infection – Some implications for nephrology by Annette Bruchfeld
/in NEP Summary Articles /by ERAPersonalized diagnosis and CKD prediction in genetic tubular disorders by Francesca Becherucci
/in NEP Summary Articles /by ERAERA Operative Headquarters
Strada dei Mercati 16/A
I-43126 Parma – Italy
Phone: +39 0521 989078
E-mail: secretariat@era-online.org
ERA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom